Sickle cell disease results from a single-nucleotide substitution, leading to valine replacing the normal glutamic acid in the sixth position of the β-globin protein,
1 resulting in a propensity toward hemoglobin polymerization and sickling of red blood cells. Sickle cell disease is characterized by anemia, ongoing hemolysis, and acute and chronic vaso-occlusive complications affecting multiple organs. Hydroxyurea and periodic red blood cell transfusions can ameliorate manifestations of sickle cell disease, but hematopoietic stem cell transplantation (HSCT) is the only available curative option to date.
2-4 Approximately 400 to 500 children with sickle cell disease worldwide have undergone HSCT after myeloablative conditioning, resulting in a sickle cell disease-free survival of 95% in the most recent series.
4 Although the myeloablative conditioning allowed most of these children to achieve complete replacement of their bone marrow by that of their donors (full-donor chimerism), a smaller fraction of them demonstrated a mixture of both recipient and donor cells (mixed chimerism).
5-7 This chimeric state proved sufficient for production of donor-type red blood cells and reversion of the sickle cell disease phenotype in the absence of graft-vs-host disease.
6